2.4.0.8061300 - Disclosure - Subsequent Eventstruefalsefalse1false falsefalsec20130101to20130630http://www.sec.gov/CIK0000872912duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_SubsequentEventsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Subsequent Events [Abstract]2false 2us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; text-indent: -18pt; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt; font-weight: bold;">(13) Subsequent Events</div><div style="text-align: left;"><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">During the third quarter through August 5, 2013, the Company sold approximately 4.6 million shares of its common stock under the March 2013 Sales Agreement through an &#8220;at the market&#8221; equity offering program for net proceeds of approximately $1.8 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, funding of the Company&#8217;s clinical trials, commercialization of our products, obtaining regulatory approvals, capital expenditures and working capital. As of August 5, 2013, the Company has approximately $48.2 million remaining under the program. As a result of the sales made under the program, the exercise price of all warrants outstanding has been reduced to $0.37.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">The Company completed an evaluation of the impact of any subsequent events through the date financial statements were issued and determined there were no other subsequent events requiring disclosure in or adjustment to these financial statements.</div></div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0Subsequent EventsfalseSubsequent EventsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://delcath.com/role/SubsequentEvents12